Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not sure what 4 tests you refer to.
DD
good point. I'm surprised we still are not sure whether BH applied for BP bluecap or not, would derisk things a bit....
W$
That's assuming it passes the remaining 4 tests. There could be further delays or they could fail them - there's still risk here
colbaltblue, young enough to wait until 1 January 2023 when By-Health will be able to distribute Fruitflow as an ingredient to other businesses and manufacture, market, and sell Fruitflow based functional food and dietary supplement finished products in Mainland China, Hong Kong, Macau, Taiwan and Australia.
How soon that will start to happen in 2023, who knows, but willing to wait.
Thank you, Dr H. Yep, can only be a good thing.
Sock, I don’t think anyone knows, but I could see that FF could be promoted as part of precise nutrition examples in their training to nutrition companies. Any close links to the government can only be a good thing.
“In the future, the two parties will carry out cooperation in scientific research, standardization, industrialization, exchanges and training in the fields of precision nutrition, clinical nutrition, new functions of health food, food and health food and their raw materials“
Hi Guys,
Sock here. Been in this stock (my only one) for 11 years. Appreciate all your hard work researching. How significant is it that By Health are helping to set the standards? It seems great, but wondered if Chinese Govt have any other big players helping them as well. Thank you
I hope you're a young healthy man, Gixer! Many of us have grown old waiting for the "transformation" promised when Adam was a lad!
And BH are helping to set the standards for the health industry.
https://topic.echemi.com/a/by-health-and-china-bidding-institute-signed-a-framework-agreement-to-focus-on-the-standardization-of-the-nutrition-and-health-industry_193057.html
Exactly DP64,
We have gone from.........
Launch a few Fruitflow products to
Get Blue Cap, to
Changing the SAMRs permitted health claim register, and now
Drug research and development projects.
So far with a significant investment at By-Health's expense.
Yes it would have been nice to see some revenue from By-Health along the way but it will come.
Yes everybody will be pleasantly with By-Health achievement. The Chinese will not spend with huge amount of money and time if fruitflow will not be a star performer near future.
I wish I had bought at 0.23p , I would be in profit now if I had. At the time though I thought PXS was dead and I had lost the lot. People ( IE the head in the sand optimists ) should not berate posters that see the potential pitfalls , everyone should have thought of them prior to investing anyway . I am not expecting much from PXS after 12 years holding , hoping I will be pleasantly surprised. GLA
Very odd up 13% on very light buys , there must be more on another platform?
15-Nov-21 16:35:10 1.05 141 Buy* 1.48 UT
They've done an uncrosser, so perhaps there won't be one.
Shenanigans. think we've all got used to it.
Except Naz.
MMs don't want anyone to buy today - wonder how big the LT will be today
Bit early on a Monday for philosophical questions Naz.
You've been here long enough to know that it's all tactics, and could change instantly if any substantial trade occurs.
Colbalt, I don’t understand your intentions here. If your so bitter about this, why not sell up and move on? Why hold and slate it constantly.
Currently pxs revenues are approx 500k. Are you telling me that you cannot see an easy path to say 5m in revenue? So only 10x from here?
Byhealth selling in China will easily create that kind of revenue for pxs. That could take pxs share price to 5-10p.
Timeline has been very long, and I can’t say I am happy with the board over these past 10+ years. But the above is quite possible with approval in China.
Just my thoughts, but there is risk in everything of course !
Yep.
Just you.
Thanks Gixer.
I think one of the 'others' on the board has been suggesting that DSM were about to walk away from the agreement rather than complete negotiations, but that doesn't seem likely if they are funding pilot studies and looking at new ways of using FF.
Thanks again for the research and insight.
Cardio Fortis
From Hungary I think
https://multivitaminbolt.com/Cardio-Fortis-30-db-kapszula-Fruitflow-kivonattal-resveratrol-rutin
Barbershop,
Funding for the pilot study was provided by DSM Nutritional Products and the Preprint of the study seems to indicate that they (DSM) could be looking at personalizing the dosage of Fruitflow.
"Despite the limitations of this study, the data generated suggests that that a larger study which addresses
the bias contained in this pilot study should be undertaken to confirm that the efficacious dose range for
Fruitflow® is between 75mg and 300mg; that personalizing the dosage of Fruitflow® could be an option
to deliver optimal effects, given the observable heterogeneity of the response between individuals; and
besides, that further investigation of TGC as a surrogate marker for monitoring the effects of the
intervention on platelet function is warranted."
https://assets.researchsquare.com/files/rs-479553/v1/b85d9d3c-0329-4a9a-a980-1fff8fbbd814.pdf?c=1631883204
The above would then lead you to the next question (well it did to me), and that is. Why?
The only answer that I can think of is that DSM have relatively recently invested $100 Million in Health tech company Hologram Sciences to launch personalized health & nutrition innovations.
"Backed by DSM, Hologram seeks to disrupt nutrition marketplace by offering consumer-facing personalized solutions"
https://www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2021-04-05-health-tech-company-hologram-sciences-launches-personalized-health-and-nutrition-Innovation-with-us-100-million-backing.html
https://www.nutraingredients-usa.com/Article/2021/04/08/Royal-DSM-launches-personalized-health-tech-company
https://hologramsciences.com/
BWTFDIK :-)
Thanks Gixer.
Always find your post to be the most informative, but I'm finding this one raising a few questions as used to seeing phase I, phase II, phase III et al, so wasn't too sure what to make of 'pilot study' on this one.
So the question I have on this is who has funded the study and what's it leading to. Has it been done to generate noise, or will there be clinical trials to follow?
Not sure what the intention is here. Followed the link, but can't seem to find the paper.....
Our latest paper "Evaluation of the equivalence of different intakes of Fruitflow in affecting platelet aggregation and thrombin generation capacity in a randomized, double-blinded pilot study in male subjects" by Das, R, Datta, T., Biswas, D., Duss, R., O'Kennedy, N., & Duttaroy, A.K. is now accepted for publication in BMC Nutrition Journal.
https://www.facebook.com/asimkduttaroy/posts/296545209138158